Midgard Science

MINIMUM bio

Surry Hills, Australiaminimumbio.comFrom their website, Nov 2026

Work here? Claim this listing

About

MINIMUM bio develops a molecular glue drug discovery platform that identifies protein targets for bioactive compounds and builds rapalog libraries for new drug discovery. It works with small molecules, biologics, and molecular glues in oncology, immunology, and longevity. The company has labs in Austin, Texas, and Sydney, Australia.

Services

  • Proteome-wide drug target discovery

    Identifies binding partners for a bioactive compound across the human proteome without a prior target hypothesis.

  • Mechanism-of-action deconvolution

    Resolves the targets of phenotypically active compounds to clarify how they work.

  • Drug repositioning support

    Uses target discovery to help identify new uses for existing compounds.

  • Off-target identification

    Finds binding partners beyond the intended target for a compound.

  • Molecular glue discovery

    Screens compounds against proteome-wide libraries to identify FKBP-recruiting molecular glue targets.

  • Rapalog library co-development

    Develops FKBP12-recruiting rapamycin analog libraries with partners.

Turnaround
1-2 weeks

Capabilities

Assays and studies
  • Small molecules
  • Phage biopanning
  • Target identification
  • Iterative screening
  • Next-generation sequencing readout
Scale and capacity
Thousands to millions of rapamycin analogs
Therapeutic areas
  • Oncology
  • Immunology
  • Longevity

Instruments and platforms

  • Next-generation sequencing

Modalities and species

Modalities
  • Small molecule
  • mRNA
  • Gene editing
Species and models
  • Human proteome
  • T7 phage
  • Phage-displayed cDNA libraries

Details

Team
50% female, 80% PhDs
Office
1601 Elm Street Dallas TX 75201 USA
Sites
Dallas, USA · Austin, USA · Sydney, Australia

Similar labs